人基因重组红细胞生成素对慢性肾功能衰竭未透析患者贫血的疗效和肾功能的影响  

Effects of recombinant human erythropoietin on anemia and renal function in pre-dialysis patients

作　　者：丁小强[1] 廖履坦[1] 吴兆龙[1] 徐元钊[1] 陶凤武[1] 

机构地区：[1]上海医科大学中山医院肾内科,上海200032

出　　处：《中国临床药学杂志》1998年第3期101-101,共1页Chinese Journal of Clinical Pharmacy

基　　金：卫生部基金资助(编号96-1-169)

摘　　要：目的:观察人基因重组红细胞生成素(rHuEPO)对慢性肾功能衰竭未透析患者贫血的疗效和肾功能的影响.方法:39例患者rHuEPO起始剂量100IU/kg,每周3次sc,观察5～30mo.结果:rHuEPO治疗20wk后所有患者贫血明显纠正,平均Hct由(18±2)%上升至(32±3)%(P<0.001),生活质量显著提高.治疗早期Hct上升幅度尿毒症未透析组显著低于氮质血症组.尿毒症未透析组rHuEPO维持剂量显著高于氮质血症组.分别为(150±57.7)和(275.0±42.5)IU·kg^(-1)·wk^(-1)(P<0.01).以血Cr倒数为指标,治疗期间患者肾功能恶化速度与治疗前无显著差别.治疗期间50%患者BP升高.结论:rHuEPO能有效纠正慢性肾功能衰竭未透析患者贫血,不加速肾功能恶化.AIM: To examine the effects of recombinant human erythropoietin (rHuEPO) on the anemia and the rate of renal function deterioration of chronic renal failure in pre-dialy-sis patients. METHODS: 9 azotemic and 30 uremic patients were treated with rHuEPO sub-cutaneously at the dose of 100IU/kg three times weekly for 5~30 months. RESULTS: The anemia responded to rHuEPO in all patients. The mean Hct increased from (0. 18±0. 02)to (0. 32±0. 03). The response was better in azotemic patients than that in uremic patients. The mean maintenance dose was(150±57. 7) and (275±42. 5)IU · kg^(-1) · wk^(-1) in azotemic and uremic patients respectively (P<0. 01). The rate of the decline in renal function,as measured by serial determination of the reciprocal of the serum creatinine concerntration, did not change significantly as the Hct rose during rHuEPO therapy while 50% patients experienced increased blood pressure. CONCLUSION: rHuEPO is effective in correcting anemia of pre-dialysis patients without affecting renal function,although it may be associated with an increase in blood pressure.

关 键 词：红细胞生成素 慢性 肾功能衰竭 贫血 肾功能 

分 类 号：R692.505[医药卫生—泌尿科学] R556[医药卫生—外科学]